Details of the Drug Combination

General Information of Drug Combination (ID: DCKVELM)

• Drug Combination Name: BIO-300 + Amonafide
• Indication: Lung adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  BIO-300 (DMJ7NVI): N.A.
  Amonafide (DMAH59S): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: EKVX
  Zero Interaction Potency (ZIP) Score: 1.49
  Bliss Independence Score: 3.93
  Loewe Additivity Score: 3.03
  LHighest Single Agent (HSA) Score: 8.12

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DC2XRPS	HL-60(TB)	Investigative	[5]
Anaplastic large cell lymphoma	DCFWU2Y	SR	Investigative	[5]
Astrocytoma	DCL4WO5	SNB-19	Investigative	[5]
Chronic myelogenous leukemia	DC36X6W	K-562	Investigative	[5]
Clear cell renal cell carcinoma	DC1G5G5	786-0	Investigative	[5]
Clear cell renal cell carcinoma	DCU4X53	TK-10	Investigative	[5]
Glioblastoma	DCHAS80	SNB-75	Investigative	[5]
Papillary renal cell carcinoma	DCQTJUY	ACHN	Investigative	[5]
Colon adenocarcinoma	DCQS7U0	COLO 205	Investigative	[6]
Invasive ductal carcinoma	DC9MV0H	HS 578T	Investigative	[6]
Malignant melanoma	DC8HW9K	LOX IMVI	Investigative	[1]
Malignant melanoma	DCQ9NIE	UACC62	Investigative	[1]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
• [2] Clinical pipeline report, company report or official report of Humanetics.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
• [5] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [6] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165